Ramalingam Compares Third Generation EGFR TKI Osimertinib to Older Agents in NSCLC
Suresh S. Ramalingam, MD, discusses how the EGFR tyrosine kinase inhibitor osimertinib compared with other EGFR inhibitors for patients with EGFR-mutant lung cancer.
Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses how the EGFR tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) compared with other EGFR inhibitors for patients withEGFR-mutant lung cancer.
As a third-generation EGFR inhibitor, osimertinib is very specific for EGFR compared with other EGFR inhibitors. The tolerability profile is also more favorable because osimertinib has fewer effects on the wildtypeEGFR-bearing cells, says Ramalingam.
Osimertinib also has better CNS penetration than the other EGFR TKIs. Research has shown that 40% to 45% of patients withEGFRmutations will develop brain metastases during the course of their disease at some point, so having an agent like osimertinib which has better CNS penetration is important. Finally, Ramalingam says that osimertinib can inhibit T790M, in addition to exon 19 and exon 21.
For more information from Ramalingam on osimertinib inEGFR-mutant lung cancer:https://www.targetedonc.com/news/updated-flaura-data-support-fda-approval-of-osimertinib-in-egfr-nsclc.
Need for Systemic Therapy Remains in Sarcoma
November 27th 2023In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Read More
BRUIN MCL-321 Trial Evaluates Pirtobrutinb Monotherapy in MCL
November 20th 2023In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
Read More
FDA to Review sBLA for Amivantamab Plus Chemo in EGFRm Advanced NSCLC
November 20th 2023Positive findings from the MARIPOSA-2 study of amivantamab with chemotherapy with or without lazertinib in locally advanced or metastatic non–small cell lung cancer with EGFR mutations support the submission of a supplemental biologics license application to the FDA.
Read More
Neoadjuvant Pembro Plus Chemo Shows EFS Benefit at 5-Years in TNBC
November 13th 2023In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
Read More
